Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance Editorial

   


Authors: Aggen, D. H.; Chu, C. E.; Rosenberg, J. E.
Title: Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance
Abstract: Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression in metastatic biopsies is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies. See related article by Klümper et al., p. 1496. ©2023 American Association for Cancer Research.
Keywords: genetics; metabolism; pathology; bladder tumor; urinary bladder neoplasms; monoclonal antibody; antibodies, monoclonal; cell adhesion molecules; carcinoma, transitional cell; transitional cell carcinoma; cell adhesion molecule; nectins; humans; human; enfortumab vedotin; nectin
Journal Title: Clinical Cancer Research
Volume: 29
Issue: 8
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2023-04-15
Start Page: 1377
End Page: 1380
Language: English
DOI: 10.1158/1078-0432.Ccr-22-3882
PUBMED: 36749325
PROVIDER: scopus
PMCID: PMC10106381
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152591124&doi=10.1158%2f1078-0432.CCR-22-3882&partnerID=40&md5=82b367b86d292734d231bdea16155d23
Notes: Export Date: 1 May 2023 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jonathan Eric Rosenberg
    513 Rosenberg
  2. David Henry Aggen
    57 Aggen
  3. Carissa Ellen Chu
    13 Chu
Related MSK Work